- 2026.03.16Our CEO Shingo Nakamura to Give Presentation at CPHI Japan 2026!
- 2026.03.13Participation in Swiss Biotech Day 2026
- 2026.03.13Our CSO, Morishita, give a presentation at Drug Discovery Chemistry 2026
- 2026.02.19Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member
- 2026.02.12Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP]
- 2026.02.12Company Presentation
- 2026.02.12Financial Results - Fiscal Year Ended December 31, 2025
- 2026.01.26SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter
- 2026.01.19The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS
- 2026.01.15Veritas In Silico to Announce FY2025 Financial Results on February 12
- 2025.12.22Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline
- 2025.12.15Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System “Perfusio”
- 2025.11.17Start of Joint Research Project with Shimane University Aimed at Developing a Novel Drugs to Suppress Post-Lung Transplant Dysfunction
- 2025.11.04Dexerials Corporation and Veritas In Silico announce Start of Joint Technology Development for Establishing High-Speed and High-Accurate Spectroscopic RNA Structure Measurement Methods
- 2025.09.24The Jikei University School of Medicine and Veritas In Silico announce Start of Joint Research for Fundamentally Enhancing Therapeutic Effects while Reducing Side Effects of Pharmaceuticals
- 2025.07.28Veritas In Silico Receives Notice of Allowance in the U.S.
- 2025.07.03Mitsubishi Gas Chemical and Veritas In Silico Announce Joint Research Agreement for Drug Discovery and Establishment of Manufacturing Methods for Nucleic Acid Drugs
- 2025.05.23Shionogi and Veritas In Silico Announce Milestone Achievement in Joint Drug Discovery Research of mRNA-targeted Small Molecules
- 2024.06.19Veritas In Silico Announces Milestone Achievement in Collaborative Research with Takeda
- 2024.02.08Veritas In Silico Listed on the Growth Market of the Tokyo Stock Exchange
- 2026.03.16Our CEO Shingo Nakamura to Give Presentation at CPHI Japan 2026!
- 2026.03.13Participation in Swiss Biotech Day 2026
- 2026.03.13Our CSO, Morishita, give a presentation at Drug Discovery Chemistry 2026
- 2026.01.15Veritas In Silico to Announce FY2025 Financial Results on February 12
- 2025.11.18[Invited Lecture] Our CSO to Present at Boston International Summit: AI-Driven Innovations in RNA-Targeted Drug Discovery
- 2025.10.28Veritas In Silico to Participate in The 42nd Medicinal Chemistry Symposium
- 2025.10.28(Scheduled for Nov. 12) Our Researcher to Present at ISNAC2025
- 2025.10.15Veritas In Silico to Announce Financial Results for the Third Quarter of FY2025 on November 11
- 2025.09.30Notice of Participation in Japan Healthcare Venture Summit 2025
- 2025.05.12(Scheduled for May 21) General Manager of our Shin-Kawasaki Research Institute to Present Research Results at 11th Novalix Conference
- 2026.02.19Appointing Candidates for Directors, Auditor, and Alternate Audit & Supervisory Board Member
- 2026.02.12Summary of Non-consolidated Financial Results for the Fiscal Year ended December 31, 2025 [Under Japanese GAAP]
- 2026.02.12Company Presentation
- 2026.02.12Financial Results - Fiscal Year Ended December 31, 2025
- 2026.01.26SpiroChem and Veritas In Silico Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter
- 2026.01.19The Jikei University School of Medicine and Veritas In Silico announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting ALS
- 2026.01.05Upgrading the Drug Discovery Platform ibVIS to aibVIS
- 2025.12.22Patent Application for the mRNA-Targeted Nucleic Acid Drugs in the In-house Pipeline
- 2025.12.15Company Presentation
- 2025.12.15Completion of Patent Examination and Patent Grant Procedures for Drug Delivery System "Perfusio"
